MedPath

DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. logo
๐Ÿ‡ฏ๐Ÿ‡ตJapan
Ownership
Subsidiary
Established
2010-01-01
Employees
10K
Market Cap
$79B
Website
http://daiichisankyo.us

Edoxaban Management in Diagnostic and Therapeutic Procedures

Completed
Conditions
Atrial Fibrillation
Venous Thromboembolism
Interventions
Procedure: Edoxaban
First Posted Date
2016-10-31
Last Posted Date
2020-02-05
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1197
Registration Number
NCT02950168

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

Completed
Conditions
Giant Cell Tumors
First Posted Date
2016-10-28
Last Posted Date
2023-10-31
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
183
Registration Number
NCT02948088
Locations
๐Ÿ‡บ๐Ÿ‡ธ

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California San Francisco, San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 12 locations

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Phase 3
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Edoxaban-based Regimen
Drug: VKA-based Regimen
First Posted Date
2016-10-25
Last Posted Date
2022-03-24
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1426
Registration Number
NCT02943785
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Alabama at Birmingham, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Arizona Sarver Heart Center, Tucson, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Arkansas Site Management Services, Little Rock, Arkansas, United States

and more 227 locations

Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2016-10-25
Last Posted Date
2022-06-01
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
13980
Registration Number
NCT02944019
Locations
๐Ÿ‡ฆ๐Ÿ‡น

Wahlarzt Ordination, Dr. Paul Pinter, Altenmarkt, Altenmarkt, Austria

๐Ÿ‡ฆ๐Ÿ‡น

Krankenhaus St. Josef Braunau, Innere Medizin 2, Braunau, Braunau Am Inn, Austria

๐Ÿ‡ฆ๐Ÿ‡น

Landeskrankenhaus Feldkirch, Kardiologie, Feldkirch, Feldkirch, Austria

and more 720 locations

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Phase 1
Completed
Conditions
Pulmonary Embolism
Thrombotic Disease
Interventions
First Posted Date
2016-10-04
Last Posted Date
2023-04-19
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
134
Registration Number
NCT02923115
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Pulmonary Associates of Mobile, Mobile, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cedars-Sinai Medical Center, Beverly Hills, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California, San Diego (UCSD) Medical Center, San Diego, California, United States

and more 43 locations

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Phase 3
Completed
Conditions
Venous Thromboembolism (VTE)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Interventions
Drug: Standard of Care
First Posted Date
2016-06-14
Last Posted Date
2025-02-28
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
290
Registration Number
NCT02798471
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Banner University Medical Center, Tucson, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital Los Angeles, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

UCLA Medical Center CAR, Los Angeles, California, United States

and more 137 locations

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2016-06-06
Last Posted Date
2019-02-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
26
Registration Number
NCT02790671
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Worldwide Clinical Trials, San Antonio, Texas, United States

A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2016-06-06
Last Posted Date
2019-02-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
12
Registration Number
NCT02790684
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Worldwide Clinical Trials, San Antonio, Texas, United States

An Open Study Assessing the Safety and Tolerability of U3-1784

Phase 1
Terminated
Conditions
Advanced Solid Tumors
Hepatocellular Cancer (HCC)
Interventions
First Posted Date
2016-02-24
Last Posted Date
2018-05-16
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
10
Registration Number
NCT02690350
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

The Royal Marsden Hospital, Sutton, Surrey, United Kingdom

๐Ÿ‡ฌ๐Ÿ‡ง

Guy's Hospital, London, United Kingdom

๐Ÿ‡ฌ๐Ÿ‡ง

The Christie NHS Foundation Trust, Manchester, United Kingdom

Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 2
Withdrawn
Conditions
Neuropathic Pain
Diabetes
Interventions
First Posted Date
2016-02-04
Last Posted Date
2016-07-27
Lead Sponsor
Daiichi Sankyo
Registration Number
NCT02673866
ยฉ Copyright 2025. All Rights Reserved by MedPath